Natera, Inc. (NASDAQ:NTRA – Get Free Report) insider Jonathan Sheena sold 2,700 shares of the business’s stock in a transaction dated Wednesday, September 18th. The shares were sold at an average price of $127.57, for a total transaction of $344,439.00. Following the completion of the sale, the insider now owns 284,741 shares in the company, valued at $36,324,409.37. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.
Jonathan Sheena also recently made the following trade(s):
- On Thursday, August 15th, Jonathan Sheena sold 12,000 shares of Natera stock. The shares were sold at an average price of $121.01, for a total transaction of $1,452,120.00.
- On Monday, August 12th, Jonathan Sheena sold 2,700 shares of Natera stock. The shares were sold at an average price of $113.82, for a total transaction of $307,314.00.
- On Monday, July 1st, Jonathan Sheena sold 2,700 shares of Natera stock. The stock was sold at an average price of $108.87, for a total value of $293,949.00.
Natera Trading Up 0.5 %
NASDAQ NTRA opened at $127.78 on Friday. Natera, Inc. has a 12 month low of $36.90 and a 12 month high of $132.01. The company has a market capitalization of $15.69 billion, a price-to-earnings ratio of -40.96 and a beta of 1.53. The company has a debt-to-equity ratio of 0.34, a current ratio of 4.14 and a quick ratio of 4.01. The firm’s fifty day moving average price is $114.45 and its 200 day moving average price is $105.43.
Analyst Upgrades and Downgrades
NTRA has been the topic of several research reports. Jefferies Financial Group began coverage on shares of Natera in a research report on Monday, June 3rd. They set a “buy” rating and a $142.00 price target on the stock. Piper Sandler reissued an “overweight” rating and issued a $150.00 price target on shares of Natera in a research report on Friday, September 13th. TD Cowen increased their price objective on Natera from $137.00 to $145.00 and gave the company a “buy” rating in a research note on Friday, August 9th. Robert W. Baird lifted their price objective on Natera from $117.00 to $120.00 and gave the company an “outperform” rating in a research note on Friday, August 9th. Finally, StockNews.com lowered shares of Natera from a “hold” rating to a “sell” rating in a research note on Wednesday, August 28th. One research analyst has rated the stock with a sell rating and fifteen have issued a buy rating to the company. According to MarketBeat.com, Natera currently has an average rating of “Moderate Buy” and a consensus price target of $120.07.
Get Our Latest Stock Analysis on NTRA
Institutional Investors Weigh In On Natera
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Itau Unibanco Holding S.A. purchased a new position in shares of Natera during the second quarter worth approximately $28,000. Quarry LP grew its position in Natera by 148.4% during the 2nd quarter. Quarry LP now owns 318 shares of the medical research company’s stock worth $34,000 after purchasing an additional 190 shares during the last quarter. GAMMA Investing LLC increased its stake in Natera by 50.0% in the second quarter. GAMMA Investing LLC now owns 324 shares of the medical research company’s stock valued at $35,000 after purchasing an additional 108 shares during the period. YHB Investment Advisors Inc. purchased a new stake in shares of Natera in the first quarter valued at about $36,000. Finally, Principal Securities Inc. acquired a new stake in shares of Natera during the fourth quarter worth about $32,000. Hedge funds and other institutional investors own 99.90% of the company’s stock.
Natera Company Profile
Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.
Further Reading
- Five stocks we like better than Natera
- Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
- Take Advantage of Village Farms Stock as Cannabis Market Evolves
- How Investors Can Find the Best Cheap Dividend Stocks
- MarketBeat Week in Review – 9/16 – 9/20
- NYSE Stocks Give Investors a Variety of Quality Options
- Don’t Miss These 3 Retail Stocks for Fall Gains
Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.